Drugs / GenSci145
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07407504 | Apr 2026 → Nov 2028 expected | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | Changchun GeneScience Pharmaceutical Co., Ltd. | Regulatory GenSci: Two Innovations Granted IND Clearance by FDA genscigroup.com ↗
Recently, GenSci145 and GenSci136 have both secured FDA clinical trial approvals, developed respectively for PIK3CA -mutated locally advanced or metastatic solid tumors and myasthenia gravis (MG). |
| 2026-04-27 | Changchun GeneScience Pharmaceutical Co., Ltd. | Results GenSci Presents Multiple Innovative Oncology Pipelines at AACR 2026 genscigroup.com ↗
Preclinical studies have verified that this candidate exhibits prominent antitumor activity in a variety of PIK3CA mutant tumor models with excellent blood-brain barrier penetration and effective inhibition of brain metastases. |
| 2026-01-16 | Changchun GeneScience Pharmaceutical Co., Ltd. | Regulatory GenSci Unveils Seven Innovative Pipeline at JPM 2026 genscigroup.com ↗
GenSci145, a selective inhibitor of PI3Kα mutant, received IND approval from the NMPA in December 2025. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci: Two Innovations Granted IND Clearance by FDA genscigroup.com ↗ |
| 2026-04-27 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci Presents Multiple Innovative Oncology Pipelines at AACR 2026 genscigroup.com ↗ |
| 2026-01-16 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci Unveils Seven Innovative Pipeline at JPM 2026 genscigroup.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenSci145 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07407504 ↗ |